加载中
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
收盘时
US$9.83
−US$0.565 · -5.44%
盘后
US$9.8303
+US$0.0003 · +0.00%
10月13日 19:44 ET
盘中时间采用ET。市场数据可能有所延迟。
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
日内区间
当前US$9.83
52周区间
当前US$9.83
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
88
深度低估
情绪
53
多空交织
风险
39
中等风险
动量
64
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
日内区间
当前US$9.83
52周区间
当前US$9.83
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$23.88
上涨空间 142.93%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3541.16万0.00%2.3万亿 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI2755.29万0.27%103.03亿 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM2264.69万0.03%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF1307.25万0.01%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO815.26万0.06%137.9亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB704.58万0.07%107.38亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO618.88万0.03%180亿 USD0.06%US$111.77-0.45%
Fidelity Enhanced Small Cap ETFFESM549.23万0.08%64.1亿 USD0.28%US$45.15-0.20%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
